XOMA (NASDAQ:XOMA) Downgraded by Zacks Investment Research

XOMA (NASDAQ:XOMA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Friday, Zacks.com reports.

According to Zacks, “XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company’s flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. “

Other research analysts also recently issued reports about the company. ValuEngine downgraded XOMA from a “hold” rating to a “sell” rating in a research report on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of XOMA in a research note on Friday, December 6th. Finally, TheStreet upgraded XOMA from a “d+” rating to a “c” rating in a report on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. XOMA presently has a consensus rating of “Hold” and an average price target of $26.33.

Shares of XOMA stock traded up $0.51 on Friday, hitting $24.36. The company’s stock had a trading volume of 1,455 shares, compared to its average volume of 75,000. XOMA has a 52-week low of $11.50 and a 52-week high of $28.85. The company has a quick ratio of 4.37, a current ratio of 4.37 and a debt-to-equity ratio of 1.31. The firm has a fifty day moving average price of $25.53 and a 200-day moving average price of $20.60. The company has a market capitalization of $208.74 million, a P/E ratio of -14.96 and a beta of 1.23.

XOMA (NASDAQ:XOMA) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported $0.20 EPS for the quarter, topping the consensus estimate of ($0.48) by $0.68. XOMA had a negative net margin of 10.19% and a negative return on equity of 8.93%. The business had revenue of $8.86 million for the quarter. As a group, analysts expect that XOMA will post -0.21 earnings per share for the current year.

In other XOMA news, CEO James R. Neal sold 4,348 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $22.00, for a total transaction of $95,656.00. Following the sale, the chief executive officer now owns 22,017 shares in the company, valued at approximately $484,374. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Bvf Partners L. P/Il bought 373,195 shares of the stock in a transaction on Thursday, December 19th. The shares were bought at an average price of $22.00 per share, for a total transaction of $8,210,290.00. The disclosure for this purchase can be found here. 9.89% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the business. Paloma Partners Management Co acquired a new stake in shares of XOMA during the second quarter worth $510,000. Marshall Wace LLP purchased a new stake in shares of XOMA in the second quarter valued at $434,000. Morgan Stanley grew its position in shares of XOMA by 2,151.6% in the second quarter. Morgan Stanley now owns 23,889 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 22,828 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in XOMA in the third quarter valued at $244,000. Hedge funds and other institutional investors own 37.20% of the company’s stock.

XOMA Company Profile

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.

Recommended Story: What does the Producer Price Index (PPI) tell investors?

Get a free copy of the Zacks research report on XOMA (XOMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.